The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice
Open accessAbstract
Senescence is a cellular defense mechanism that helps cells prevent acquired damage, but chronic senescence, as in aging, can contribute to the development of age-related tissue dysfunction and disease. Previous studies clearly show that removal of senescent cells can help prevent tissue dysfunction and extend healthspan during aging. Senescence increases with age in the skeletal system, and selective depletion of senescent cells or inhibition of their senescence-associated secretory phenotype (SASP) has been reported to maintain or improve bone mass in aged mice. This suggests that promoting the selective removal of senescent cells, via the use of senolytic agents, can be beneficial in the treatment of aging-related bone loss and osteoporosis. Navitoclax (also known as ABT-263) is a chemotherapeutic drug reported to effectively clear senescent hematopoietic stem cells, muscle stem cells, and mesenchymal stromal cells in previous studies, but its in vivo effects on bone mass had not yet been reported. Therefore, the purpose of this study was to assess the effects of short-term navitoclax treatment on bone mass and osteoprogenitor function in old mice. Aged (24 month old) male and female mice were treated with navitoclax (50 mg/kg body mass daily) for two weeks. Surprisingly, despite decreasing senescent cell burden, navitoclax treatment decreased trabecular bone volume fraction in aged female and male mice (-60.1% females, -45.6% males), and BMSC-derived osteoblasts from the navitoclax treated mice were impaired in their ability to produce a mineralized matrix (-88% females, -83% males). Moreover, in vitro administration of navitoclax decreased BMSC colony formation and calcified matrix production by aged BMSC-derived osteoblasts, similar to effects seen with the primary BMSC from the animals treated in vivo. Navitoclax also significantly increased metrics of cytotoxicity in both male and female osteogenic cultures (+1.0 to +11.3 fold). Taken together, these results suggest a potentially harmful effect of navitoclax on skeletal-lineage cells that should be explored further to definitively assess navitoclax’s potential (or risk) as a therapeutic agent for combatting age-related musculoskeletal dysfunction and bone loss.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some senolytics may cause severe reductions in platelets or neutrophils.
“Some studies have found that some senolytics may cause severe reductions in platelets or neutrophils [112, 113].”
From Modulation of fracture healing by senescence-associated secretory phenotype (SASP): a narrative review of the current literature (2024) · cites this paper as [112]
The Introduction (page unavailable) reports that navitoclax has toxic side effects including transient thrombocytopenia and neutropenia, supporting reductions in platelets or neutrophils. It does not characterize those reductions as severe. (LLM, conf=0.84)
Experimental — accuracy not yet measuredSome studies reported trabecular bone loss and impaired bone formation in BMSC in aged mice after using Navitoclax (ABT-263).
“some studies reported trabecular bone loss and impaired bone formation in BMSC in aged mice after using Navitoclax (ABT-263) [112].”
From Modulation of fracture healing by senescence-associated secretory phenotype (SASP): a narrative review of the current literature (2024) · cites this paper as [112]
ABT263 treatment in aged female and male mice reduced trabecular bone volume fraction (by 60.1% in females and 45.6% in males) and the ability of osteoblasts derived from bone marrow stem cells to produce mineralised matrix (by 88% in females and 83% in males), despite decreasing the burden of senescent cells.
“However, another study showed that, despite decreasing the burden of senescent cells, ABT263 treatment in aged female and male mice reduced both trabecular bone volume fraction (by 60•1% in females and by 45•6% in males) and the ability of osteoblasts derived from bone marrow stem cells to produce mineralised matrix (by 88% in females and by 83% in males).35”
From The costs and benefits of senotherapeutics for human health (2022) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670 · cited 2× · see citing works
“For example, inducible elimination of p16Ink4a-positive senescent cells delayed onset of age related pathologies and improved physical function in old (26–28 month) mice (Baker et al., 2011; Xu et al., 2018).”
BackgroundABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058 · see citing works
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623 · cited 1× · see citing works
“…cells prevent acquired damage; acute senescence can be beneficial in processes related to wound healing, injury repair, and development, but chronic senescence, as in aging, can contribute to the development of age-related tissue dysfunction and disease (Van Deursen, 2014; Calcinotto et al., 2019).”
BackgroundThe Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,562 · see citing works
Dempster, D. W., Compston, J. E., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., Recker, R. R., & Parfitt, A. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1805 · Cited by 2,543 · see citing works
Senolytics improve physical function and increase lifespan in old age
Xu, M., Pirtskhalava, T., Farr, J. N., Weigand, B. M., Palmer, A. K., Weivoda, M. M., Inman, C. L., Ogrodnik, M. B., Hachfeld, C. M., Fraser, D. G., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0092-9 · Cited by 2,287 · see citing works
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Chang, J., Wang, Y., Shao, L., Laberge, R.-M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N. E., Ding, S., Feng, W., et al. (2016) · Nature Medicine · doi:10.1038/nm.4010 · Cited by 1,819 · see citing works
Hickson, L. J., Langhi Prata, L. G. P., Bobart, S. A., Evans, T. K., Giorgadze, N., Hashmi, S. K., Herrmann, S. M., Jensen, M. D., Jia, Q., Jordan, K. L., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.069 · Cited by 1,383 · cited 1× · see citing works
“…+ quercetin senolytic drug combination mentioned above (Xu et al., 2018), have been tested to see the target effect on senescent cells and amelioration of aging or disease phenotypes (Grezella et al., 2018), with some even entering clinical trials (Hickson et al., 2019; Justice et al., 2019).”
BackgroundCellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270 · see citing works
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Justice, J. N., Nambiar, A. M., Tchkonia, T., LeBrasseur, N. K., Pascual, R., Hashmi, S. K., Prata, L., Masternak, M. M., Kritchevsky, S. B., Musi, N., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.052 · Cited by 1,261 · see citing works
Targeting cellular senescence prevents age-related bone loss in mice
Farr, J. N., Xu, M., Weivoda, M. M., Monroe, D. G., Fraser, D. G., Onken, J. L., Negley, B. A., Sfeir, J. G., Ogrodnik, M. B., Hachfeld, C. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4385 · Cited by 1,182 · cited 1× · see citing works
“Accordingly, senolytic therapies that target and remove these cells hold enormous promise for the treatment of age-related diseases, including osteoporosis (Baker et al., 2011; Chang et al., 2016; Farr et al., 2017; Grezella et al., 2018; Khosla et al., 2018; Geng et al., 2019; Kim and Kim, 2019).”
BackgroundZhu, Y., Tchkonia, T., Fuhrmann‐Stroissnigg, H., Dai, H. M., Ling, Y. Y., Stout, M. B., Pirtskhalava, T., Giorgadze, N., Johnson, K. O., Giles, C. B., et al. (2016) · Aging Cell · doi:10.1111/acel.12445 · Cited by 1,148 · see citing works
Langenbach, F., & Handschel, J. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt328 · Cited by 662 · cited 1× · see citing works
“…that is commonly added to osteogenic cultures at low dosages (e.g., 100 nM) to enhance osteoblastic differentiation (Yamanouchi et al., 2001; Langenbach and Handschel, 2013; Yuasa et al., 2015), but can also affect osteoblastic cell metabolism and apoptosis particularly at higher…”
BackgroundRudin, C. M., Hann, C. L., Garon, E. B., de Oliveira, M. R., Bonomi, P., Camidge, D. R., Chu, Q. S.-C., Giaccone, G., Khaira, D. K., Ramalingam, S. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3090 · Cited by 563 · cited 1× · see citing works
“It is important to remember that senolytic agents like navitoclax are non-specific in nature; navitoclax, in particular, can act upon several different Bcl-2 family target proteins to promote apoptosis (Rudin et al., 2012; Souers et al., 2013; Zhu et al., 2016).”
BackgroundIdentification of senescent cells in the bone microenvironment
Farr, J. N., Fraser, D. G., Wang, H., Jaehn, K., Ogrodnik, M. B., Weivoda, M. M., Drake, M. T., Tchkonia, T., LeBrasseur, N. K., Kirkland, J. L., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2892 · Cited by 562 · see citing works
Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2.
Lecka‐Czernik, B., Gubrij, I. B., Moerman, E. J., Kajkenova, O., Lipschitz, D. A., Manolagas, S. C., & Jilka, R. L. (1999) · PubMed · Cited by 464 · see citing works
Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR?2
Lecka‐Czernik, B., Gubrij, I. B., Moerman, E. J., Kajkenova, O., Lipschitz, D. A., Manolagas, S. C., & Jilka, R. L. (1999) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19990901)74:3 · Cited by 403 · see citing works
p16Ink4a-induced senescence of pancreatic beta cells enhances insulin secretion
Helman, A., Klochendler, A., Azazmeh, N., Gabai, Y., Horwitz, E., Anzi, S., Swisa, A., Condiotti, R., Granit, R. Z., Nevo, Y., et al. (2016) · Nature Medicine · doi:10.1038/nm.4054 · Cited by 351 · cited 1× · see citing works
“…+ quercetin senolytic drug combination mentioned above (Xu et al., 2018), have been tested to see the target effect on senescent cells and amelioration of aging or disease phenotypes (Grezella et al., 2018), with some even entering clinical trials (Hickson et al., 2019; Justice et al., 2019).”
BackgroundCoppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302 · see citing works
Dexamethasone induces osteoblast apoptosis through ROS-PI3K/AKT/GSK3β signaling pathway
Deng, S., Dai, G., Chen, S., Nie, Z., Zhou, J., Fang, H., & Peng, H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.103 · Cited by 238 · cited 2× · see citing works
“…can affect matrix mineralization, apoptosis, and mechanisms of lipid storage by osteoblasts (McGeeLawrence et al., 2016; Nie et al., 2018; Deng et al., 2019), additional cultures were seeded in osteogenic medium with no dexamethasone to determine whether glucocorticoid inclusion affected…”
BackgroundSenotherapeutics: emerging strategy for healthy aging and age-related disease
Kim, E.-C., & Kim, J. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.1.293 · Cited by 211 · cited 1× · see citing works
“Accordingly, senolytic therapies that target and remove these cells hold enormous promise for the treatment of age-related diseases, including osteoporosis (Baker et al., 2011; Chang et al., 2016; Farr et al., 2017; Grezella et al., 2018; Khosla et al., 2018; Geng et al., 2019; Kim and Kim, 2019).”
BackgroundKim, H., Chang, J., Shao, L., Han, L., Iyer, S., Manolagas, S. C., O'Brien, C. A., Jilka, R. L., Zhou, D., & Almeida, M. (2017) · Aging Cell · doi:10.1111/acel.12597 · Cited by 192 · cited 1× · see citing works
“…that is commonly added to osteogenic cultures at low dosages (e.g., 100 nM) to enhance osteoblastic differentiation (Yamanouchi et al., 2001; Langenbach and Handschel, 2013; Yuasa et al., 2015), but can also affect osteoblastic cell metabolism and apoptosis particularly at higher…”
BackgroundBeresford, J. N., Joyner, C. J., Devlin, C., & Triffitt, J. T. (1994) · Archives of Oral Biology · doi:10.1016/0003-9969(94)90077-9 · Cited by 185 · see citing works
Kaefer, A., Yang, J., Noertersheuser, P., Mensing, S., Humerickhouse, R., Awni, W., & Xiong, H. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2530-9 · Cited by 161 · cited 1× · see citing works
“Accordingly, senolytic therapies that target and remove these cells hold enormous promise for the treatment of age-related diseases, including osteoporosis (Baker et al., 2011; Chang et al., 2016; Farr et al., 2017; Grezella et al., 2018; Khosla et al., 2018; Geng et al., 2019; Kim and Kim, 2019).”
BackgroundInhibiting Cellular Senescence: A New Therapeutic Paradigm for Age-Related Osteoporosis
Khosla, S., Farr, J. N., & Kirkland, J. L. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02694 · Cited by 130 · cited 1× · see citing works
“Accordingly, senolytic therapies that target and remove these cells hold enormous promise for the treatment of age-related diseases, including osteoporosis (Baker et al., 2011; Chang et al., 2016; Farr et al., 2017; Grezella et al., 2018; Khosla et al., 2018; Geng et al., 2019; Kim and Kim, 2019).”
BackgroundYuasa, M., Yamada, T., Taniyama, T., Masaoka, T., Xuetao, W., Yoshii, T., Horie, M., Yasuda, H., Uemura, T., Okawa, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116462 · Cited by 99 · cited 1× · see citing works
“…osteogenic cultures at low dosages (e.g., 100 nM) to enhance osteoblastic differentiation (Yamanouchi et al., 2001; Langenbach and Handschel, 2013; Yuasa et al., 2015), but can also affect osteoblastic cell metabolism and apoptosis particularly at higher concentrations (e.g., 1 µM) (Nie et al.,…”
BackgroundEffects of senolytic drugs on human mesenchymal stromal cells
Grezella, C., Fernández‐Rebollo, E., Franzen, J., Ferreira, M. S. V., Beier, F., & Wagner, W. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0857-6 · Cited by 76 · see citing works
Histone deacetylase 3 is required for maintenance of bone mass during aging
McGee‐Lawrence, M. E., Bradley, E. W., Dudakovic, A., Carlson, S. W., Ryan, Z. C., Kumar, R., Dadsetan, M., Yaszemski, M. J., Chen, Q., An, K., et al. (2012) · Bone · doi:10.1016/j.bone.2012.10.015 · Cited by 74 · see citing works
Self-citationMoriishi, T., Maruyama, Z., Fukuyama, R., Ito, M., Miyazaki, T., Kitaura, H., Ohnishi, H., Furuichi, T., Kawai, Y., Masuyama, R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027487 · Cited by 68 · see citing works
McGee‐Lawrence, M. E., Shull, L. C., Schulze, R. J., Pierce, J. L., McNiven, M. A., Farr, J. N., Khosla, S., Oursler, M. J., & Westendorf, J. J. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2602 · Cited by 67 · cited 1× · see citing works
“In addition, for follow-up studies on TUNEL staining, a group of old female wildtype mice (27 months of age, n = 5) was culled from an in-house breeding colony [wildtype Osx1-Cre-negative Hdac3fl/fl mice (McGee-Lawrence et al., 2016, 2018)].”
MethodSelf-citationYamanouchi, K., Satomura, K., Gotoh, Y., Kitaoka, E., Tobiume, S., Kudoh, K., & Nagayama, M. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.5.857 · Cited by 64 · cited 1× · see citing works
“…osteogenic cultures at low dosages (e.g., 100 nM) to enhance osteoblastic differentiation (Yamanouchi et al., 2001; Langenbach and Handschel, 2013; Yuasa et al., 2015), but can also affect osteoblastic cell metabolism and apoptosis particularly at higher concentrations (e.g., 1 µM) (Nie et al.,…”
BackgroundLow-dose quercetin positively regulates mouse healthspan
Geng, L., Liu, Z., Wang, S., Sun, S., Ma, S., Liu, X., Chan, P., Sun, L., Song, M., Zhang, W., et al. (2019) · Protein & Cell · doi:10.1007/s13238-019-0646-8 · Cited by 59 · cited 6× · see citing works
“Accordingly, senolytic therapies that target and remove these cells hold enormous promise for the treatment of age-related diseases, including osteoporosis (Baker et al., 2011; Chang et al., 2016; Farr et al., 2017; Grezella et al., 2018; Khosla et al., 2018; Geng et al., 2019; Kim and Kim, 2019).”
BackgroundInfluentialBcl2 Deficiency Activates FoxO through Akt Inactivation and Accelerates Osteoblast Differentiation
Moriishi, T., Kawai, Y., Komori, H., Rokutanda, S., Eguchi, Y., Tsujimoto, Y., Asahina, I., & Komori, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086629 · Cited by 47 · cited 1× · see citing works
“…shown that Bcl-2-deficient mice demonstrated enhanced osteoblastic differentiation and increased trabecular bone mass at young ages (Moriishi et al., 2014), whereas increased expression of Bcl-2 in mice induced apoptosis of osteocytes and reduced osteoblast differentiation (Moriishi et al., 2011).”
BackgroundBlagosklonny, M. V. (2018) · Aging · doi:10.18632/aging.101750 · Cited by 15 · cited 2× · see citing works
“…and both artificial and natural agerelated increases in p16-driven senescence in pancreatic beta cells increased glucose-stimulated insulin production, suggesting that depletion of these cells (via senolytic targeting) could promote a diabetic phenotype (Helman et al., 2016; Blagosklonny, 2018).”
BackgroundMcGee‐Lawrence, M. E., Pierce, J. L., Yu, K., Culpepper, N. R., Bradley, E. W., & Westendorf, J. J. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26148 · Cited by 14 · see citing works
Self-citationNie, Z., Chen, S., Deng, S., Long, L.-S., Peng, P., Gao, M., Cheng, S., Cao, J., & Peng, H. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.10.043 · Cited by 14 · cited 2× · see citing works
“…like dexamethasone can affect matrix mineralization, apoptosis, and mechanisms of lipid storage by osteoblasts (McGeeLawrence et al., 2016; Nie et al., 2018; Deng et al., 2019), additional cultures were seeded in osteogenic medium with no dexamethasone to determine whether glucocorticoid…”
BackgroundRelationship between osteoporosis and expression of Bcl-2 and CXCL12
Pang, T., Gong, M., Han, J.-T., & Liu, D. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5513 · Cited by 13 · cited 2× · see citing works
“It is important to remember that senolytic agents like navitoclax are non-specific in nature; navitoclax, in particular, can act upon several different Bcl-2 family target proteins to promote apoptosis (Rudin et al., 2012; Souers et al., 2013; Zhu et al., 2016).”
Background
Flagged first, then by citations
Cited by
Sorted by citations
Senolytic drugs: from discovery to translation
Kirkland, J. L., & Tchkonia, T. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13141 · Cited by 1,227 · see citing works
Cellular senescence: the good, the bad and the unknown
Huang, W., Hickson, L. J., Eirin, A., Kirkland, J. L., & Lerman, L. O. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00601-z · Cited by 1,150 · see citing works
Advances in pathogenesis and therapeutic strategies for osteoporosis
Song, S., Guo, Y., Yang, Y., & Fu, D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108168 · Cited by 476 · see citing works
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 448 · see citing works
“515 Nevertheless, BH3-mimetics are currently being used as part of an effort to design more targeted second-generation senolytics, which may change the way these drugs are delivered to their targets and improve their effects.”
Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics
Chandra, A., & Rajawat, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073553 · Cited by 276 · see citing works
COVID-19 and cellular senescence
Schmitt, C. A., Tchkonia, T., Niedernhofer, L. J., Robbins, P. D., Kirkland, J. L., & Lee, S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00785-2 · Cited by 153 · see citing works
The costs and benefits of senotherapeutics for human health
Raffaele, M., & Vinciguerra, M. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00300-7 · Cited by 140 · see citing works
Tchkonia, T., Palmer, A. K., & Kirkland, J. L. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa728 · Cited by 129 · see citing works
Senolytics for Cancer Therapy: Is All that Glitters Really Gold?
Carpenter, V. J., Saleh, T., & Gewirtz, D. A. (2021) · Cancers · doi:10.3390/cancers13040723 · Cited by 124 · see citing works
Age Related Osteoporosis: Targeting Cellular Senescence
Föger‐Samwald, U., Kerschan‐Schindl, K., Butylina, M., & Pietschmann, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052701 · Cited by 121 · see citing works
“A recent study treating aged mice continuously with novitoclax (50 mg/kg/day) for two weeks, rather than intermittently, caused trabecular bone loss [94].”
BackgroundOsteoporosis remission via an anti-inflammaging effect by icariin activated autophagy
Bai, L., Liu, Y., Zhang, X., Chen, P., Hang, R., Xiao, Y., Wang, J., & Liu, C. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122125 · Cited by 119 · see citing works
Skin-Aging Pigmentation: Who Is the Real Enemy?
Kim, J. C., Park, T. J., & Kang, H. Y. (2022) · Cells · doi:10.3390/cells11162541 · Cited by 114 · see citing works
Tripathi, U., Misra, A., Tchkonia, T., & Kirkland, J. L. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111548 · Cited by 104 · see citing works
“Indeed, drugs with single or limited targets, such as navitoclax, have off-target apoptotic effects on multiple nonsenescent cell types, limiting clinical translation or requiring local application rather than systemic delivery, such as oral administration [77].”
Senescent cells and macrophages: key players for regeneration?
Elder, S. S., & Emmerson, E. (2020) · Open Biology · doi:10.1098/rsob.200309 · Cited by 109 · see citing works
Cellular Senescence: Mechanisms and Therapeutic Potential
Liao, Z., Yeo, H. L., Wong, S. W., & Zhao, Y. X. (2021) · Biomedicines · doi:10.3390/biomedicines9121769 · Cited by 86 · see citing works
Plasma dilution improves cognition and attenuates neuroinflammation in old mice
Mehdipour, M., Mehdipour, T., Skinner, C. M., Wong, N., Liu, C., Chen, C.-C., Jeon, O. H., Zuo, Y., Conboy, M. J., & Conboy, I. M. (2020) · GeroScience · doi:10.1007/s11357-020-00297-8 · Cited by 83 · see citing works
Strategies for senolytic drug discovery
Power, H., Valtchev, P., Dehghani, F., & Schindeler, A. (2023) · Aging Cell · doi:10.1111/acel.13948 · Cited by 81 · see citing works
“…results, limitations associated with activity spectrum, negative side-effects, bioavailability, and potency (Kovacovicova et al., 2018; Raffaele et al., 2021; Roberts et al., 2012; Sharma et al., 2020) necessitate ongoing research into novel senolytics and optimization of exist - ing compounds.”
BackgroundThe role of reactive oxygen species in bone cell physiology and pathophysiology
Marques-Carvalho, A., Kim, H., & Almeida, M. (2023) · Bone Reports · doi:10.1016/j.bonr.2023.101664 · Cited by 72 · see citing works
Cellular Senescence in Idiopathic Pulmonary Fibrosis
Kellogg, D. L., Kellogg, D. L., Musi, N., & Nambiar, A. M. (2021) · Current Molecular Biology Reports · doi:10.1007/s40610-021-00145-4 · Cited by 67 · see citing works
Senescence as a molecular target in skin aging and disease
Thau, H., Gerjol, B. P., Hahn, K., Gudenberg, R. W. V., Knoedler, L., Stallcup, K., Emmert, M. Y., Buhl, T., Wyles, S. P., Tchkonia, T., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102686 · Cited by 62 · see citing works
Lawrence, M., Goyal, A., Pathak, S., & Ganguly, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137411 · Cited by 54 · see citing works
“Interestingly, while Chang and colleagues demonstrated rejuvenated BM HSCs in vivo by using ABT-263 to clear senescent cells [126], another study, which evaluated the effect of navitoclax on mice, showed trabecular bone loss and musculoskeletal dysfunction [127].”
BackgroundMaurer, S., Kirsch, V., Ruths, L., Brenner, R. E., & Riegger, J. (2024) · Aging Cell · doi:10.1111/acel.14361 · Cited by 55 · see citing works
Senescent cells in cancer therapy: why and how to remove them
Zhang, J., Zhang, D., & Yu, B. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.002 · Cited by 50 · see citing works
Local Elimination of Senescent Cells Promotes Bone Defect Repair during Aging
Xing, X., Huang, H., Gao, X., Yang, J., Tang, Q., Xu, X., Wu, Y., Li, M., Cheng, L., Tan, L., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c22138 · Cited by 46 · see citing works
Senolytics: Potential for Alleviating Diabetes and Its Complications
Palmer, A. K., Tchkonia, T., & Kirkland, J. L. (2021) · Endocrinology · doi:10.1210/endocr/bqab058 · Cited by 49 · see citing works
“Navitoclax, another senolytic drug, can cause transient thrombocytopenia and direct cytotoxicity to osteoblasts (49).”
BackgroundDeryabin, P. I., Shatrova, A. N., Marakhova, I. I., Nikolsky, N. N., & Borodkina, A. V. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03980-x · Cited by 44 · see citing works
HO-1 in Bone Biology: Potential Therapeutic Strategies for Osteoporosis
Zhou, X., Yuan, W., Xiong, X., Zhang, Z., Liu, J., Zheng, Y., Wang, J., & Liu, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.791585 · Cited by 45 · see citing works
“Elimination of senescent cells can be achieved pharmacologically by long-term senolytic treatment, by clearance of p16-positive genetic cells in INK-ATTAC transgenic mice, or by blocking SASP production through the targeted inhibition of Janus kinase pathway; each of these strategies can increase bone mass and improve…”
BackgroundThe role of senolytics in osteoporosis and other skeletal pathologies
Doolittle, M. L., Monroe, D. G., Farr, J. N., & Khosla, S. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111565 · Cited by 44 · see citing works
Senescent cells: A therapeutic target for osteoporosis
Wang, T., Huang, S., & He, C. (2022) · Cell Proliferation · doi:10.1111/cpr.13323 · Cited by 43 · see citing works
“2 weeks, with mice exhibiting trabecular bone loss in the proximal tibia, which contributed to impaired osteo-progenitor function.(218)”
BackgroundTakaya, K., Asou, T., & Kishi, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115704 · Cited by 42 · see citing works
“However, some of these drugs had serious side effects [18], and people are increasingly seeking natural and safer antioxidant and anti-aging drugs.”
BackgroundZheng, L., He, S., Wang, H., Li, J., Liu, Y., & Liu, S. (2024) · Aging and Disease · doi:10.14336/ad.2024.0206 · Cited by 44 · see citing works
“However, some studies have also reported potential damage to navitoclax on osteocytes [156], and further studies are needed to confirm this view.”
Activatable senoprobes and senolytics: Novel strategies to detect and target senescent cells
Morsli, S., Doherty, G. J., & Muñoz‐Espín, D. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111618 · Cited by 41 · see citing works
Gil, T., Zheng, H., Lee, H. G., Shin, J.-W., Hwang, S. W., Jang, K.-M., & Jeon, O. H. (2022) · Aging · doi:10.18632/aging.204204 · Cited by 46 · see citing works
“ABT263 has potential adverse effects on osteoprogenitor function and bone loss [45].”
BackgroundSenotherapeutics and Their Molecular Mechanism for Improving Aging
Park, J., & Shin, D. W. (2022) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2022.114 · Cited by 43 · see citing works
“However, this compound caused trabecular bone loss and damages the function of osteoprogenitors in aged mice (Sharma et al., 2020).”
Takaya, K., & Kishi, K. (2024) · Biogerontology · doi:10.1007/s10522-024-10103-z · Cited by 43 · see citing works
“However, these drugs are associated with adverse side effects (Kirkland et al. 2017; Sharma et al. 2020), leading to renewed focus on the development of novel compounds capable of selectively eliminating senescent cells.”
Recent advances in senescence-associated secretory phenotype and osteoporosis
Fan, H., Qiao, Z., Li, J., Shang, G., Shang, C., Chen, S., Leng, Z., Su, H., Kou, H., & Liu, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25538 · Cited by 42 · see citing works
Unveiling mechanisms of lung aging in COPD: A promising target for therapeutics development
Devulder, J. V. (2024) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2024.08.007 · Cited by 41 · see citing works
Zhao, S., Qiao, Z., Pfeifer, R., Pape, H.-C., Mao, K., Tang, H., Meng, B., Chen, S., & Liu, H. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01604-7 · Cited by 35 · see citing works
“However, some studies reported trabecular bone loss and impaired bone formation in BMSC in aged mice after using Navitoclax (ABT-263) [112].”
BackgroundTeissier, T., Temkin, V., Pollak, R. D., & Cox, L. S. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.812157 · Cited by 35 · see citing works
Senolytic treatment for low back pain
Mannarino, M., Cherif, H., Darband, S. G., Martinez, O. W., Sheng, K., Cousineau, E., Lee, S., Millecamps, M., Gao, C., Gilbert, A., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr1719 · Cited by 33 · see citing works
Setiawan, S. A., Liu, W. Z., Weng, P., Lee, C., Yadav, V. K., Hardianti, M. S., Yeh, C., & Chao, T. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175526 · Cited by 33 · see citing works
Mesenchymal stromal cell senescence in haematological malignancies
Plakhova, N., Panagopoulos, V., Vandyke, K., Zannettino, A. C. W., & Mrozik, K. M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10069-9 · Cited by 33 · see citing works
“However, while navitoclax has been shown to effectively clear senescent cells in murine [174, 175] and human [176] BM-MSC cultures in vitro, its utility to eliminate senescent BM-MSCs in vivo is yet to be investigated.”
BackgroundChen, M., Han, H., Zhou, S.-Q., Wen, Y.-X., & Chen, L.-B. (2021) · Stem cell research & therapeutics · doi:10.1186/s13287-021-02239-3 · Cited by 25 · see citing works
Ionic liquid-mediated delivery of a BCL-2 inhibitor for topical treatment of skin melanoma
Huda, M. N., Deaguero, I. G., Borrego, E. A., Kumar, R., Islam, T., Afrin, H., Varela-Ramı́rez, A., Aguilera, R. J., Tanner, E. E. L., & Nurunnabi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.035 · Cited by 28 · see citing works
Escriche‐Navarro, B., Garrido, E. M. N., Sancenón, F., García‐Fernández, A., & Martínez‐Máñez, R. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.01.002 · Cited by 27 · see citing works
Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing
Shvedova, M., Thanapaul, R. J. R. S., Ha, J., Dhillon, J., Shin, G. H., Crouch, J. D., Gower, A. C., Gritli, S., & Roh, D. S. (2024) · Aging · doi:10.18632/aging.206165 · Cited by 26 · see citing works
Senotherapeutics for mesenchymal stem cell senescence and rejuvenation
Wong, P., Murugan, D. D., & Ramasamy, T. S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103424 · Cited by 24 · see citing works
Takaya, K., Ishii, T., Asou, T., & Kishi, K. (2022) · Rejuvenation Research · doi:10.1089/rej.2022.0048 · Cited by 24 · see citing works
Dhokia, V., Albati, A., Smith, H., Thomas, G., & Macip, S. (2024) · Biochemical Society Transactions · doi:10.1042/bst20231066 · Cited by 25 · see citing works
Tumorigenic Aspects of MSC Senescence—Implication in Cancer Development and Therapy
Mojsilović, S. B., Jauković, A., Кукољ, Т., Obradović, H., Djordjević, I. O., Petrović, A., & Bugarski, D. S. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111133 · Cited by 23 · see citing works
Fournier, F., Diaz-Marin, R., Pilon, F., Neault, M., Juneau, R., Girouard, G., Wilson, A. M., Larrivée, B., Mallette, F. A., Crespo‐Garcia, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2209973120 · Cited by 23 · see citing works
Chu, J. C. H., Escriche‐Navarro, B., Xiong, J., García‐Fernández, A., Martínez‐Máñez, R., & Ng, D. K. P. (2024) · Advanced Science · doi:10.1002/advs.202401012 · Cited by 20 · see citing works
The Role of Senescence-Associated Secretory Phenotype in Bone Loss
Zhu, R., Wan, H., Yang, H. S., Song, M., Chai, Y., & Yu, B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.841612 · Cited by 21 · see citing works
Pan, C. C., Maeso‐Díaz, R., Lewis, T. R., Xiang, K., Tan, L., Liang, Y., Wang, L., Yang, F., Yin, T., Wang, C., et al. (2023) · Cell Research · doi:10.1038/s41422-023-00820-4 · Cited by 19 · see citing works
Yang, C., Qiao, W., Xue, Q., Goltzman, D., Miao, D., & Zhan, D. (2024) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2024.08.012 · Cited by 19 · see citing works
“Our findings of the protective effect of ABT-263 on bone in vitamin D insufficient mice appear to conflict with a recent report by Sharma et al. [34], which demonstrated that ABT-263 causes trabecular bone loss and impairs osteoprogenitor function in aged mice.”
ResultThe ageing immune system as a potential target of senolytics
Du, P. Y., Gandhi, A., Bawa, M., & Gromala, J. (2023) · Oxford Open Immunology · doi:10.1093/oxfimm/iqad004 · Cited by 18 · see citing works
“Navitoclax also exhibited cytotoxicity against osteoblasts and bone marrow progenitor cells in mice through a currently unknown mechanism, resulting in a significant loss of bone mass [78].”
BackgroundTargeting cellular senescence to combat cancer and ageing
Wang, C., Hao, X., & Zhang, R. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13266 · Cited by 19 · see citing works
Immunosenescence and the Geriatric Giants: Molecular Insights into Aging and Healthspan
Fetarayani, D., Kahdina, M., Waitupu, A., Pratiwi, L., Ningtyas, M. C., Adytia, G. J., & Sutanto, H. (2025) · Medical Sciences · doi:10.3390/medsci13030100 · Cited by 14 · see citing works
Selective Elimination of Senescent Fibroblasts by Targeting the Cell Surface Protein ACKR3
Takaya, K., Asou, T., & Kishi, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126531 · Cited by 14 · see citing works
“The senescent cell eliminators ABT737 [18] and ABT263 [19] are BH3 mimetic inhibitors of antiapoptotic proteins (Bcl-xL, Bcl-2, and Bcl-w) originally developed for cancer therapy; however, the inhibition of Bcl-xL was found to have serious side effects [20].”
BackgroundPLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia
Shah, K., Nasimian, A., Ahmed, M., Ashiri, L. A., Denison, L., Sime, W., Bendak, K., Kolosenko, I., Siino, V., Levander, F., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00914-7 · Cited by 13 · see citing works
“However, this type of inhibition seems to have strong side effects [27, 28].”
BackgroundGut aging: A wane from the normal to repercussion and gerotherapeutic strategies
Abankwah, J. K., Wang, Y., Wang, J., Enechojo, O. S., Pozzo, L. D., Chu, X., & Bian, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37883 · Cited by 13 · see citing works
Shah, K., Ashiri, L. A., Nasimian, A., Ahmed, M., & Kazi, J. U. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24055004 · Cited by 11 · see citing works
Venz, R., Goyala, A., Soto-Gamez, A., Yenice, T., Demaria, M., & Ewald, C. Y. (2023) · GeroScience · doi:10.1007/s11357-023-00909-z · Cited by 11 · see citing works
“We, therefore, asked if the treatment of senolytic drugs like quercetin and navi-toclax in C. elegans could reduce the β-gal staining.”
BackgroundFalvino, A., Bonanni, R., Tarantino, U., Tancredi, V., & Cariati, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157573 · Cited by 11 · see citing works
“Sharma et al. observed significant loss of trabecular bone tissue and impaired BMSCs function in aged mice treated with navitoclax for 2 weeks, in association with reduced mineralized matrix production and decreased expression of the osteoprogenitor gene Osx [7].”
InfluentialTherapy-Induced Tumor Cell Senescence: Mechanisms and Circumvention
Zamkova, M. A., Александровна, П. Н., Tatarskiy, V. V., & Shtil, A. A. (2023) · Biochemistry (Moscow) · doi:10.1134/s000629792301008x · Cited by 9 · see citing works
“However, its application is limited due to development of thrombocytopenia and neutropenia, which determine general resorptive toxicity [14, 132, 133].”
BackgroundCellular senescence in age-related musculoskeletal diseases
Xiong, J., Guo, Q., & Luo, X. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1125-7 · Cited by 10 · see citing works
Habiballa, L., Hruby, A. J., Granic, A., Dodds, R. M., Hillman, S. J., Jurk, D., Passos, J. F., & Sayer, A. A. (2023) · GeroScience · doi:10.1007/s11357-023-00869-4 · Cited by 9 · see citing works
Cellular Senescence and Senolytic Agents: Recent Updates on Their Role and Applications
Chandrakar, L., Ambatwar, R., & Khatik, G. L. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266273698231107110956 · Cited by 10 · see citing works
Recent Advancement in Elimination Strategies and Potential Rejuvenation Targets of Senescence
Kureel, S. K., Blair, B., & Sheetz, M. P. (2023) · Advanced Biology · doi:10.1002/adbi.202300461 · Cited by 8 · see citing works
Regulation of ENPP5, a senescence-associated secretory phenotype factor, prevents skin aging
Takaya, K., & Kishi, K. (2024) · Biogerontology · doi:10.1007/s10522-024-10096-9 · Cited by 8 · see citing works
“However, these therapies have severe side effects (Sharma et al. 2020) and have not yet been approved for clinical application.”
Geroprotectors and Skeletal Health: Beyond the Headlines
Rayson, A., Boudiffa, M., Naveed, M., Griffin, J., Dall’Ara, E., & Bellantuono, I. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.682045 · Cited by 7 · see citing works
Mesenchymal Stem Cell Senescence and Biomaterial-Based Next-Generation Rejuvenation Strategy
ZHANG, Y. A., Judeh, R., Aravind, S., Zreiqat, H., & Lu, Z. (2025) · Tissue Engineering Part B Reviews · doi:10.1177/19373341251372962 · Cited by 6 · see citing works
Escriche‐Navarro, B., Garrido, E., Escudero, A. C., Montoya-Méndez, I., Sancenón, F., García‐Fernández, A., & Martínez‐Máñez, R. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123461 · Cited by 6 · see citing works
Pharmacological frontiers in senescence: Transforming senescence with drug repurposing
Shahzadi, A., Özyazgan, S., & Çakatay, U. (2025) · Advances in pharmacology · doi:10.1016/bs.apha.2025.02.010 · Cited by 5 · see citing works
Horestani, M. H., & Baniahmad, A. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10302-1 · Cited by 5 · see citing works
“Navitoclax (ABT-263), a BCL-2/BCL-XL family inhibitor originally developed as an anti-cancer drug, selectively eliminates senescent cells dependent on BCL-2 family survival signaling; however its use is limited by tissue toxicity [122].”
In vitro senescence and senolytic functional assays
Ryan, P., & Lee, J. (2025) · Biomaterials Science · doi:10.1039/d4bm01684j · Cited by 6 · see citing works
The potential for senotherapy as a novel approach to extend life quality in veterinary medicine
Williams, Z. J., Chow, L., Dow, S., & Pezzanite, L. M. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1369153 · Cited by 5 · see citing works
SATB1, senescence and senescence‐related diseases
Qi, W., Bai, J., Wang, R., Zeng, X., & Zhang, L. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31327 · Cited by 5 · see citing works
Luffman, N., Ahmadinejad, F., Finnegan, R., Raymond, M., Gewirtz, D. A., & Harada, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136185 · Cited by 5 · see citing works
Chen, B., Li, G., Fang, Q., Ding, P., & Gao, Y. (2026) · Inflammation and Regeneration · doi:10.1186/s41232-026-00416-6 · Cited by 5 · see citing works
“In aged mice with bone loss, treat-ment with D + Q significantly reduced the number of senescent osteoclasts and partially restored bone remodeling efficiency [160].”
InfluentialChronic Kidney Disease and Cellular Senescence
Morevati, M., Tavenier, J., Scheibye‐Knudsen, M., Houlind, M. B., Hedayati, A., & Hornum, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073205 · Cited by 4 · see citing works
“Certain senolytic drugs, like navitoclax, can lead to side effects such as neutropenia, trabecular bone loss, and dysfunction of osteoprogenitor cells [252,253].”
Takaya, K., Asou, T., & Kishi, K. (2023) · Biogerontology · doi:10.1007/s10522-023-10043-0 · Cited by 4 · see citing works
“However, the safety of these newly developed agents has not been established, and serious side effects have been reported (Sharma et al. 2020; Al-Asmakh et al. 2021).”
BackgroundA Conversation with ChatGPT on Contentious Issues in Senescence and Cancer Research
Elshazly, A. M., Shahin, U., Shboul, S. A., Gewirtz, D. A., & Saleh, T. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.124.000871 · Cited by 4 · see citing works
“For instance, navitoclax, which has been shown to be the most effective senolytic in tumor cell models undergoing TIS, is associated with significant thrombocytopenia, impaired osteoblast function and neutropenia (de Vos et al., 2021; Karnewar et al., 2023; Sharma et al., 2020).”
BackgroundResearch Progress of Senolytic Drugs in the Treatment of Orthopedic Diseases
Zhang, M., Lou, P., Shou, D., Tong, P., & Zhang, Y. (2025) · Gerontology · doi:10.1159/000543386 · Cited by 4 · see citing works
“According to the research by Sharma [76], treatment with navitoclax reduced the trabecular bone volume fraction in aged mice and hindered the capacity of osteoblasts to generate a mineralized matrix.”
Antisenescence therapies for age‐related bone loss: Target factors, medicines, biomedical materials
Zhu, Q., Hu, M., Wu, L., Wei, E., Pan, X., Liu, H., & Liu, Y. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70350 · Cited by 4 · see citing works
“67 Therefore, the antisenescence and osteogenesis-promoting effects of Navitoclax still need to be refined.”
EndoCompass project: research roadmap for calcium and bone endocrinology
Jähn, K., Zibar, K., Anastasilakis, A. D., Bertocchio, J., Brandi, M. L., Faßnacht, M., Cheung, M., Gevers, E. F., Gittoes, N. J. L., Mäkitie, O., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf064 · Cited by 5 · see citing works
Kaempferol-loaded mechanical-enhanced aerogel for augmenting osteoporotic bone regeneration
Jin, X., Huang, P., Cao, X., Wang, X., Mao, Z., & Li, Z. (2025) · Materials & Design · doi:10.1016/j.matdes.2025.113996 · Cited by 4 · see citing works
Wang, P., Yang, M.-Y., Liu, W., & Chen, C. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114963 · Cited by 3 · see citing works
Zhang, D., Zhu, J., Zou, R., Zhang, H., Yu, B.-P., Li, P., Luo, Y., Jiang, Z., Hou, Y., & Zhang, J.-W. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117659 · Cited by 3 · see citing works
Mechanisms and mediators of disease
Devulder, J. V., & Donnelly, L. (2024) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006423 · Cited by 3 · see citing works
Miwa, S., Fielder, E., Ishaq, A., Low, E., Laws, J., Calista, A., Castle, J., & von Zglinicki, T. (2024) · doi:10.59368/agingbio.20240022 · Cited by 4 · see citing works
“…clinical trials of patients with lymphoid tumors, at least 40% of patients reported thrombocytopenia at a dose of about 3–4 mg/kg/day 5,6 This is similar to what has been reported in rodents, and higher doses of Navitoclax have shown increased pulmonary hypertension 8 and bone loss in aged mice 9 .”
Senolytic Phytocompounds in Redox Signaling
Thirumurugan, K. (2021) · Healthy ageing and longevity · doi:10.1007/978-3-030-84965-8_12 · Cited by 3 · see citing works
Skeletal Aging and Osteoporosis: Cellular Senescence and BeyondPreprint
Chandra, A., & Rajawat, J. (2021) · Preprints.org · doi:10.20944/preprints202102.0127.v1 · Cited by 2 · see citing works
“However, judgement should always side with caution, since senolytic drugs may work for recovering some aged related tissue dysfunction[188], but not for osteoporosis, as in the case with Navitoclax/ABT-263[204].”
ResultThe Role of Senolytics in Osteoporosis
Chen, E., Zhang, J., Chen, H., & Li, W. (2025) · Biomolecules · doi:10.3390/biom15081176 · Cited by 6 · see citing works
“Interestingly, unlike other senolytic agents, navitoclax does not inhibit osteoporosis but rather induces bone loss [124].”
Senolytic therapy increases replicative capacity by eliminating senescent endothelial cells
Abdeahad, H., Moreno, D. G., Bloom, S. I., Huang, H., Lesniewski, L. A., & Donato, A. J. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112885 · Cited by 2 · see citing works
Alameen, A. A. M., Al‐kuraishy, H. M., Fawzy, M. N., & Batiha, G. E. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05309-6 · Cited by 3 · see citing works
Salas-Venegas, V., López‐Díazguerrero, N. E., Carreto, R. J. R., Königsberg, M., & Chavarría, A. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1824908 · Cited by 2 · see citing works
Senescence-Induced Atherosclerosis: The Potency of Senolytic Therapy
Ratih, U. S., & Iswanti, F. C. (2024) · Bioscientia Medicina Journal of Biomedicine and Translational Research · doi:10.37275/bsm.v8i8.1036 · Cited by 2 · see citing works
“72 Navitoclax targets the Bcl-2 family of proteins, including Bcl-2, Bcl-xL, and Bcl-w, which are major negative regulators of apoptosis.”
BackgroundSenescence in Aging, Within the Brain and Other Diseases: Mechanisms and Interventions
Chakrabarti, S. K., & Chattopadhyay, D. (2023) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2023.00018 · Cited by 2 · see citing works
DRUGS WITH SENOLYTIC ACTIVITY: PROSPECTS AND POSSIBLE LIMITATIONS
Васильевна, М. Г., & Khokhlov, A. N. (2024) · Vestnik Moskovskogo universiteta Seria 16 Biologia · doi:10.55959/msu0137-0952-16-78-4-3 · Cited by 2 · see citing works
- Authors
- Sharma, A. K., Roberts, R. L., Benson, R. D., Pierce, J. L., Yu, K., Hamrick, M. W., & McGee-Lawrence, M. E.
- Affiliations
- Augusta University (US)
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2020-05-20
- Volume
- 8
- Pages
- 354-354
- ISSN
- 2296-634X (ISSN-L)
- PMC
- PMC7252306
- OpenAlex
- W3027385411
- Cited by
- 131
- References
- 37
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 23 · 2023: 23 · 2022: 24 · 2021: 15 · 2020: 4
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Cell and Developmental Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute on Aging
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- navitoclax, senolytics, cellular senescence, trabecular bone loss, bone marrow mesenchymal stem cells, osteogenic differentiation, bone mass, aging, senescence-associated secretory phenotype, adverse drug reactions, sex differences, cytotoxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
